Repligen (NASDAQ:RGEN) Upgraded by StockNews.com to Hold Rating

StockNews.com upgraded shares of Repligen (NASDAQ:RGEN) from a sell rating to a hold rating in a research note released on Friday.

A number of other equities research analysts have also weighed in on the stock. Canaccord Genuity Group raised their price target on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a report on Friday, February 21st. JPMorgan Chase & Co. raised their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. Royal Bank of Canada raised their price objective on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research note on Friday, February 21st. Finally, TD Cowen initiated coverage on Repligen in a report on Monday, February 10th. They set a “buy” rating and a $200.00 price objective on the stock. Seven research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and a consensus target price of $178.64.

Repligen Trading Down 8.0 %

NASDAQ:RGEN opened at $111.94 on Friday. Repligen has a 12 month low of $106.78 and a 12 month high of $182.52. The business’s 50-day moving average is $150.03 and its two-hundred day moving average is $147.51. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm has a market capitalization of $6.29 billion, a PE ratio of -219.49, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Research analysts predict that Repligen will post 1.72 earnings per share for the current fiscal year.

Insider Transactions at Repligen

In related news, Director Margaret Pax purchased 250 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the transaction, the director now owns 1,043 shares of the company’s stock, valued at $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

Several large investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD boosted its holdings in shares of Repligen by 11.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock valued at $1,027,165,000 after acquiring an additional 743,815 shares during the period. Vanguard Group Inc. grew its position in Repligen by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company’s stock worth $734,251,000 after purchasing an additional 56,723 shares during the last quarter. Champlain Investment Partners LLC increased its stake in shares of Repligen by 8.6% in the fourth quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company’s stock valued at $222,176,000 after purchasing an additional 122,595 shares during the period. Alliancebernstein L.P. raised its holdings in shares of Repligen by 23.4% during the fourth quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company’s stock valued at $145,508,000 after buying an additional 191,439 shares during the last quarter. Finally, Conestoga Capital Advisors LLC boosted its position in shares of Repligen by 0.7% during the fourth quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company’s stock worth $136,395,000 after buying an additional 6,872 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.